ProCE Banner Activity

Choosing a Single-Tablet Regimen for Initial HIV Treatment: Can 2 Drugs Be As Good As 3?

Clinical Thought
Could the anticipated first 2-drug single-tablet regimen for initial HIV treatment change the landscape for initial ART regimens?

Released: February 25, 2019

Expiration: February 24, 2020

No longer available for credit.

Share

Faculty

John Faragon

John Faragon, PharmD, BCPS, AAHIVP

Pharmacist, HIV and HCV Medicine
Albany Medical Center
Regional Pharmacy Director
Northeast/Caribbean AIDS Education and Training Center (AETC)
Albany, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Program Director Disclosure

Program Director

John Faragon, PharmD, BCPS, AAHIVP

Pharmacist, HIV and HCV Medicine
Albany Medical Center
Regional Pharmacy Director
Northeast/Caribbean AIDS Education and Training Center (AETC)
Albany, New York

John Faragon, PharmD, BCPS, AAHIVP, has disclosed that he has received fees for non-CME activities from AbbVie, Gilead Sciences, Janssen, Merck, and ViiV.